OBD partners with Goodbody Clinic on PSE test

Oxford BioDynamics PLC

23 May 2024

 

Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Oxford BioDynamics partners with Goodbody Clinic to offer
nationwide access to the EpiSwitch® PSE test

·    Goodbody Clinic to offer the EpiSwitch® Prostate Screening Test (PSE) at all its locations across the UK, supported by its network of GPs

·    Expands access to EpiSwitch® PSE simplifying both the test requisitioning and sample collection

·    Goodbody Clinic is a provider of private health tests using a network of over 140 clinics

·    Goodbody Clinic will also offer men the option of booking a nurse visit to come to their home for blood collection

Oxford, UK - 23 May 2024 - Oxford BioDynamics Plc (AIM: OBD, the "Company"), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, and the Goodbody Clinic, a nationwide provider of private health testing services, have signed an agreement to give Goodbody Clinic patients access to OBD's EpiSwitch PSE (EpiSwitch Prostate Screening) blood test.

OBD's EpiSwitch PSE test is a blood test that boosts the predictive accuracy of a standard PSA test from 55% to 94% when testing for the presence or absence of prostate cancer, which was launched in the UK and US in September 2023 (see www.94percent.com).

The Goodbody Clinic offers customers private health testing using a network of over 140 clinics nationwide. By partnering with OBD, the Goodbody Clinic will immediately offer the EpiSwitch PSE test at all its locations across the UK. Using the Goodbody Clinic website, men can request to order a PSE test from one of the clinics' registered GPs, pay for their test, and book an appointment for their blood sample to be taken at their local clinic. The Goodbody Clinic will also provide a remote doctor's referral and consultation to support patients to ensure they receive the appropriate care.

For those unable to come into one of the Goodbody clinics, men will have the option of having their PSE blood sample drawn at any location by booking a mobile nurse visit. The Goodbody Clinic operates a growing network of mobile phlebotomists across the UK, operating from Scotland down to Cornwall.

George Thomas, Chief Executive Officer of Goodbody Clinic, said: "The rapid EpiSwitch PSE test can significantly enhance the accuracy of detecting prostate cancer, allowing us to provide better care and peace of mind to men throughout the whole country. We are always looking to advance our commitment to accessible, high-quality healthcare by combining the latest innovations like the PSE with access to Goodbody's convenient clinics and home testing solutions."

To order the PSE test from the Goodbody Clinic, visit: https://health.goodbodyclinic.com/product/episwitch-pse-advanced-blood-test/

Thomas Guiel, Chief Operating Officer of Oxford BioDynamics, said: "This agreement presents an important new point of patient access for the EpiSwitch PSE test, allowing us to further extend the availability and reach of our highly accurate prostate cancer test."

The PSE test is the culmination of nearly ten years of collaborative work between OBD, Imperial College London, the University of East Anglia, Imperial College NHS Trust, and leading UK prostate cancer experts, as part of the PROSTAGRAM screening pilot. As well as a high 94% accuracy, PSE offers high specificity, 97% (standard PSA alone: 53%), and high sensitivity, 86% (PSA: 64%), as well as high positive, 93% (PSA: 25%¹), and high negative, 95% (PSA: 86%¹) predictive values to assess the risk of prostate cancer in men, published in the peer-reviewed publication, Cancers².

References

1.        NHS Health A to Z. Prostate cancer: PSA testing (2021). https://www.nhs.uk/conditions/prostate-cancer/psa-testing

2.        Pchejetski D, Hunter E, Dezfouli M, et al. (2023). Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection. Cancers. 2023; 15(3):821. https://doi.org/10.3390/cancers15030821

- Ends -

For further details please contact:
Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO	[phone]
Shore Capital (Nominated Adviser and Broker to OBD) Stephane Auton Lucy Bowden	[phone]
WG Partners (Joint Broker to OBD) David Wilson / Claes Spång / Sateesh Nadarajah / Erland Sternby	[phone]
Instinctif Partners (Media / Analyst enquiries for OBD) Melanie Toyne-Sewell / Katie Duffell / Jack Kincade	Tel: [phone] [e-mail]
Goodbody Clinic George Thomas	Tel: [phone]

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship products are the EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer, which was launched in the US and UK in September 2023.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit, which is available for purchase by the life science research community.

The Company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for the prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow OBD on Twitter (@OxBioDynamics) and LinkedIn.

About Goodbody Wellness Limited

Goodbody Wellness Limited is an aggregator of the highest quality, most innovative range of health and wellness services and products using the latest technology. With over 80 products today, tests include blood, genetic, cancer and other diagnostic solutions to meet today's fast evolving consumer expectations with more than 250,000 tests completed to date.

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 15,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcomes, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

 

END